In support of hormone therapy testing models, an ER+ breast cancer organoid medium (BTOM-ER), which conserves ER expression, estrogen responsiveness, and dependence as well as sensitivity to endocrine therapy of ER+ PDO, was developed by Oliphant et al. [102]. Here, ESR1 is linked to breast carcinoma.